Gothenburg, Sweden (PRWEB) January 27, 2015
Persomics was founded mid 2014 with a firm ambition to change the way cures are discovered. Based on great technology, Persomics empowers companies and organizations to discover cures faster. Persomics has now closed the first round of funding led by two Swedish business angels, Johan Lassing, CEO of Qamcom Technology AB and Marcus Gustavsson, chairman at AB Blåkläder and chairman of the Paradifference Foundation.
“The funds will accelerate the company’s growth and allow Persomics to commercialize its groundbreaking functional genomics screening technology,” says Martin Svensson, CEO of Persomics AB. “I am very pleased with the team we are building and with Johan Lassing and Marcus Gustavsson involved, we have a core team that will enable the business to make our products available to a large audience.”
“Through the Paradifference Foundation I have a broad network of scientists across Europe and USA, and I am convinced that the Persomics technology will change the way researchers and scientists think of and perform phenotypic screening regardless of area and organization,” says Marcus Gustavsson.
Persomics has established operational headquarters in Waltham, MA at the AstraZeneca BioHub and has additional representation in Gothenburg , Sweden and Silicon Valley, CA. First products enabling researchers and scientists to conduct large number of functional genomics experiments and phenotypic screening will be launched first half of 2015.
Persomics provides ImagineArraysTM, a technology that miniaturizes, accelerates and increases the scale of possible experiments. Researchers investigating the function of the human genome and disease are no longer limited by automation requirements or cost, but by their need to discover more. With Persomics this can be achieved at a fraction of the investment required in large industrial research labs. With our technology the science can go further, faster. For more information, please visit persomics.com
Please send enquiries to:
CEO Persomics AB